Begin with what you need
You’re aiming for clear answers, not vague promises; start by listing your primary goals, not the full protocol. Tell a potential preclinical oncology CRO whether you need tumor-growth inhibition, PK/PD correlation, biomarker proof, or dose-finding — those specifics change the study design, timelines, and cost. Be concise: primary endpoint, species/model, expected sample size, and a non-negotiable deadline. That helps the vendor respond with a realistic plan instead of a guess.
Ask practical study-design questions
Get concrete answers on randomization, blinding, group size justification, statistical tests, and how they’ll handle dropouts. Request draft protocol headers and a simple timeline. Confirm whether in-life work is GLP or non-GLP, who signs off on final reports, and how raw data are delivered. If they won’t share these basics up front, you’re setting yourself up for surprises later.
PDX considerations, with real-world grounding
Patient-derived xenografts demand specific experience: ask about engraftment rates, passage number control, and how they manage tumor heterogeneity. For a high-level industry reference, NCI’s PDXNet consortium has published standardized approaches that many labs follow; review those expectations alongside any vendor claims and compare them to their actual case history using PDX mouse model. Ask for engraftment metrics from recent studies and at least one publication or internal report that shows reproducible responses under blinded conditions.
Common pitfalls first-time buyers encounter
Don’t leave endpoints vague. Avoid assuming your vendor will propose the best statistical plan. Don’t ignore QC: request SOPs for dosing accuracy, health monitoring, and tissue handling. Watch for opaque billing — ask for line-item quotes. Neglecting data transfer formats and timelines is a frequent cause of delay; insist on previewing a sample dataset before signing the contract.
Viable alternatives and when to pick them
PDX studies are strong for translational response signals, but they’re slower and costlier. Choose organoids or 3D in vitro screens when you need broader, rapid compound triage. Use syngeneic or GEMM models when immune context is essential. Match model choice to decision points: early go/no-go — faster in vitro; late-stage translational proof — PDX or GEMM.
Quick vendor-evaluation checklist
Scan these items during an initial call: team expertise and lead scientist CVs, recent publications using your desired model, access to SOPs, quality assurance contacts, sample final reports, data formats (raw + analyzed), and IP/data ownership terms. Ask for a short reference — a lab that ran a similar study — and follow up. If timelines are tight, confirm backup capacity and contingency plans for animal colony issues.
Final synthesis
First-time buyers get better outcomes when they start from decisions they must make, then match study design and model to those decisions. That clarity reduces surprises, tightens timelines, and focuses budget where it matters; it’s also how experienced partners present their capabilities and documentation, which is why many teams like the transparent protocol summaries provided by KCI Biotech when comparing options.